Today, the U.S. Food and Drug Administration approved Xenpozyme (Olipudase alfa) for intravenous infusion in pediatric and adult patients with Acid Sphingomyelinase Deficiency (ASMD), a rare genetic disease that causes premature death. Xenpozyme is the first approved medication to treat symptoms that are not related to the central nervous system in patients with ASMD.
FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
August 31, 2022
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022